Abstract:Objective:In this study, we analyzed the efficacy and tolerability of mycophenolate mofetil and three other immunosuppressants in Graves’ ophthalmopathy (GO) patients. Methods:Fifty four untreated GO patients were enrolled in this study. The diagnosis of GO was based on the presence of the typical clinical features and excluding of the possibility of cranial/orbital diseases, and the severity of ophthalmopathy was at least equal to or more severe than Class 2 in NO SPECS classification. Those who could afford were randomly assigned to receive either mycophenolate mofetil (MMF, n =12, 16～18 mg per kilogram per day) or cyclosporin A (CsA, n =11, 5～6 mg per kilogram of body weight per day) therapy. The others were randomly assigned to be given either prednisone ( n =16, finished in 13 case, 40 mg per day for 4 weeks, 20 mg for 4 weeks, and 10 mg for 4 weeks) or tripterygium multi glycosides (T Ⅱ , n =15, 30～60 mg per day). The disease severity and therapeutic response were quantitatively assessed according to the Ophthalmopathy Index Scoring System from Given wilson (1989) with sensibly modified. The improvement or progression of ophthalmopathy was defined if the variation, either increase or decrease of the score, reached 3 or more in the ophthalmopathy index. If this did not occur, a lack of response was indicated. In patients who had hyperthyroidism, antithyroid drugs were also administered.Results:After 12 week therapy, 7 (54 percent) of the 13 treated with prednisone improved, the remaining 6 (46 percent) lacked response. In T Ⅱ group, 10 (67 percent) of 15 responded to the therapy, 5 (33 percent) had no change. There was no significant difference in clinical response between the above 2 groups ( P 0.05). Five CsA treated and 11 MMF treated patients responded to therapy (45 percent vs 92 percent; P 0.05) . It seems that MMF is more effective than CsA in the treatment of GO although a significant decrease ( P 0.01) in the mean score of the CsA group has also been shown at the end of the course. None of all the 51 patients in the 4 groups had worsening of ophthalmopathy. Among 16 patients in prednisone group, 3 (19 percent) gained body weight by more than 5 percent, 2 (13 percent) developed impaired glucose tolerance (IGT). These two patients and one of the three weight gaining patients ceased the therapy. Impermanent menopause happened in 1 (11 percent) of the females in T Ⅱ group at the sixth month in sequel treatment after the course. Conclusion:MMF may be more effective than CsA in the treatment of Graves’ophthalmopathy. T Ⅱ may have a equal effectiveness and perhaps a better tolerability than prednisone in the immunotherapy of Graves’ ophthalmopathy.

Therapeutic Progress in Graves' Ophthalmopathy

Recent Advances in Graves Ophthalmopathy Medical Therapy: a Comprehensive Literature Review.

Treatment Modalities for Graves' Ophthalmopathy

Study Progress of High Dose Intravenous Glucocorticoid Pulse Therapy in the Treatment of Thyroid-associated Ophthalmopathy

Thyroid-associated ophthalmopathy: cu-rrent concepts regarding etiopathogenesis and management

Research Progress on the Pathogenesis of Graves’ Ophthalmopathy: Based on Immunity, Noncoding RNA and Exosomes

Understanding Pathogenesis Intersects With Effective Treatment for Thyroid Eye Disease

Cytokines as Targets of Novel Therapies for Graves' Ophthalmopathy

Immunosuppressive therapies in patients with Graves' ophthalmopathy]

Bayesian network analysis of drug treatment strategies for thyroid associated ophthalmopathy

[Research status of potential therapeutic targets for thyroid-associated ophthalmopathy]

Pediatric aspects in Graves' orbitopathy

Thyroid eye disease: From pathogenesis to targeted therapies

Therapeutic Outcomes of Mycophenolate Mofetil and Three Other Immunosuppressants in Patients with Graves’ Ophthalmopathy

New Therapeutic Horizon of Graves’ Hyperthyroidism: Treatment Regimens Based on Immunology and Ingredients From Traditional Chinese Medicine

[Graves' orbitopathy: Current concepts for medical treatment]

Epidemiology, Natural History, Risk Factors, and Prevention of Graves’ Orbitopathy

Transition from hypothyroidism to Graves' disease, development of thyroid eye disease, progression to optic neuropathy after inpatient pulse therapy, and long-term administration of outpatient pulse therapy: a case report with review of literature

The Stepwise Establishment of Standardized Treatment for the Thyroid Eye Disease

Future Projections in Thyroid Eye Disease

Graves' Orbitopathy: Current Concepts for Medical Treatment